London · Delayed Price · Currency is GBP · Price in GBX GSK plc Earnings Call Transcripts
Fiscal Year 2026
-
Major clinical milestones are expected this year for camlipixant in chronic cough and bepirovirsen in hepatitis B, both targeting significant unmet needs. The R&D strategy emphasizes validated mechanisms, differentiation, and AI-driven innovation, with a broad pipeline in respiratory and specialty medicine.
-
No major strategic changes are planned under new leadership, with continued focus on core therapy areas and pipeline acceleration. Recent M&A targets scientifically de-risked assets, while new product launches in respiratory, oncology, and HIV are progressing well. Long-acting HIV therapies and broader respiratory segmentation are key growth drivers.
-
Significant pipeline momentum was highlighted, with multiple late-stage assets, key approvals in respiratory and oncology, and advances in hepatitis B and HIV. AI and partnerships are driving R&D productivity, while business development focuses on long-acting agents and near-term growth.
Fiscal Year 2025
-
Sales rose 7% to over £32 billion in 2025, led by Specialty Medicines and strong HIV and vaccine growth. Core profit and EPS grew double digits, with robust cash flow and increased dividends. 2026 guidance targets continued growth, with focus on new launches and pipeline acceleration.
-
R&D strategy emphasizes immune system science, technology integration, and capital allocation between internal and external assets. Oncology, respiratory, and HIV pipelines are advanced through targeted acquisitions, collaborations, and long-acting treatments, with key milestones expected in hepatitis B, COPD, and ADCs. Asset selection is driven by scientific, clinical, and economic criteria.
-
Q3 2025 saw 8% sales growth, 11% core operating profit growth, and 14% EPS growth, driven by Specialty Medicines, Oncology, and HIV. Upgraded guidance for 2025 reflects strong momentum, robust R&D progress, and continued investment in innovation and shareholder returns.
-
Upgraded guidance reflects strong specialty and HIV growth, with oncology and respiratory assets driving momentum. Multiple launches and positive phase III data underpin confidence, while regulatory and pricing challenges are being actively managed. Key products like Blenrep, depemokimab, and Shingrix are expected to outperform consensus.
-
Q2 2025 saw 6% sales growth, 12% core operating profit growth, and 15% EPS growth, driven by specialty medicines and vaccines. Guidance for 2025 was raised to the top end, with robust R&D progress, strong cash generation, and major launches planned for H2.
-
Q1 2025 saw 4% sales growth and 5% EPS increase, led by Specialty Medicines and strong HIV momentum, offsetting vaccine declines. Guidance for 2025 is reaffirmed, with robust cash flow, increased shareholder returns, and continued R&D investment supporting long-term growth.
-
Key 2025 drivers include Blenrep's relaunch, Nucala's COPD entry, and Shingrix's evolving strategy. Blenrep aims for broad use with strong survival data, while vaccine and specialty portfolios target growth through new indications and global expansion.
-
Strong sales and profit growth in 2024 were driven by specialty medicines and vaccines, with five major product launches planned for 2025. The pipeline is robust, featuring advances in oncology, respiratory, and HIV, and capital allocation remains focused on R&D and shareholder returns.
Fiscal Year 2024
-
2024 saw 8% sales growth to over GBP 31 billion, led by specialty medicines and strong HIV and oncology performance, offsetting vaccine headwinds. Outlook for 2025 is continued profitable growth, with five major approvals expected and a GBP 2 billion share buyback announced.
-
Significant R&D momentum is driving a robust pipeline in oncology, respiratory, and liver disease, with multiple late-stage assets, innovative biomarker strategies, and increased investment in high-growth areas. Regulatory catalysts and data readouts are expected to sustain growth through the decade.
-
Strong sales and profit growth continue, driven by specialty medicines and a robust pipeline with multiple late-stage assets. Vaccines face near-term headwinds but maintain long-term growth ambitions, while disciplined capital allocation supports innovation and shareholder returns.
-
Clear R&D focus on vaccines, infectious diseases, respiratory, and oncology is driving portfolio growth. Arexvy and Shingrix show strong efficacy, with new data and label expansions expected. Key late-stage assets like gepotidacin, Bepirovirsen, Depemokimab, and Blenrep are advancing toward major milestones.
-
Significant progress has been made in pipeline prioritization, specialty and vaccine growth, and balance sheet transformation. Upgraded long-term outlooks, strong business development, and a focus on innovation and AI position the company for continued growth, with robust performance in HIV, oncology, and international markets.
-
Year-to-date sales grew 9% and profit 19%, led by specialty medicines and strong HIV, oncology, and respiratory performance. Despite vaccine headwinds and U.S. policy risks, guidance for 2024 is reaffirmed, with confidence in long-term growth and pipeline launches.
-
Management highlighted strong execution, upgraded financial guidance, and a robust specialty care and vaccine pipeline. Arexvy and Shingrix are key growth drivers, with international expansion and innovation in HIV and oncology. Zantac litigation remains a monitored risk.
-
Q2 saw 13% sales growth and 21% core operating profit increase, driven by strong specialty medicines, HIV, and general medicines. Upgraded 2024 guidance reflects confidence in continued growth, despite US vaccine headwinds and ongoing Zantac litigation.
-
Significant progress is being made across the oncology portfolio, with Blenrep showing strong efficacy and manageable safety in multiple myeloma, and Jemperli and Zejula expanding into new indications. Strategic focus on ADCs and immuno-oncology combinations positions the pipeline for robust growth and differentiation.